Microscopy System Aids Analysis of Breast Cancer Test

Called Ariol HerSight, the system has been cleared by the U.S. Food and Drug Administrastion (FDA).

Special testing is required to identify those women who are HER2-positive and thus candidates for treatment with Herceptin. The Ariol Hersight application helps pathologists determine whether the HER2 protein is over-expressed in breast cancer tissues that are being evaluated in routine laboratory settings. Herceptin is a targeted therapeutic treatment indicated for women with metastatic breast cancer whose tumors overexpress the HER2 protein. The Ariol Hersight system was developed by Applied Imaging Corp., (Santa Clara, CA, USA), a supplier of automated imaging systems for the analysis of chromosomes in cancer and prenatal disorders.

"HerSight and other Ariol applications under development address the pressing clinical challenge of how best to assess which breast cancer patients should receive a powerful targeted therapeutic agent,” noted Carl Hull, CEO of Applied Imaging.




Related Links:
Applied Imaging